Veeramani Anamika, McCarty Justin C, Vieira Brittany L, Karinja Sarah, Pusic Andrea L, Carty Matthew J, Erdmann-Sager Jessica
Division of Plastic and Reconstructive Surgery, Brigham and Women's Hospital, Boston, Mass.
Plast Reconstr Surg Glob Open. 2022 Apr 25;10(4):e4244. doi: 10.1097/GOX.0000000000004244. eCollection 2022 Apr.
Factor V Leiden (FVL) is the most common inherited thrombophilia in White people. Thrombotic complications resulting from free flap breast reconstruction in FVL patients have been studied to a limited degree. We evaluated whether patients heterozygous for a FVL mutation undergoing deep inferior epigastric perforator flap reconstruction had increased risk of micro- or macrovascular thrombotic complications compared with patients without a diagnosed thrombophilia.
We performed a retrospective cohort study of deep inferior epigastric perforator flap reconstructions at Brigham and Women's Hospital (1/2015-12/2020) comparing patients diagnosed as FVL heterozygotes compared with matched controls without a diagnosed thrombophilia. Patients were matched using coarsened exact matching algorithm based on clinical characteristics. The primary outcomes were micro- (return to OR for flap compromise, flap loss) and macrovascular (venous thromboembolism) complications.
A total of 506 patients (812 flaps) were included in this study. Eleven patients (17 flaps) were FVL heterozygotes. After matching, 10 patients (16 flaps) with FVL were matched to 55 patients (94 flaps). The return to OR for flap compromise was 0% in the FVL cohort compared with 5% (n = 5/94, 3/94 flaps lost, = 1.00) in the matched controls (1.9%, n = 15/795 in unmatched controls, 0.6%, n = 5/795 loss rate). There were zero venous thromboembolism events among FVL patients compared with 2% of controls (n = 1/55).
FVL heterozygosity did not increase the risk of micro- or macrovascular complications in patients undergoing deep inferior epigastric perforator flap breast reconstruction. This study supports the safety of microvascular reconstruction in this group of patients when appropriate venous thromboembolism prophylaxis is given.
因子V莱顿突变(FVL)是白种人中最常见的遗传性易栓症。FVL患者游离皮瓣乳房重建导致的血栓并发症研究程度有限。我们评估了与未诊断出易栓症的患者相比,携带FVL突变的杂合子患者在接受腹壁下深动脉穿支皮瓣重建时发生微血管或大血管血栓并发症的风险是否增加。
我们对布莱根妇女医院(2015年1月至2020年12月)进行的腹壁下深动脉穿支皮瓣重建进行了一项回顾性队列研究,比较诊断为FVL杂合子的患者与未诊断出易栓症的匹配对照。根据临床特征使用粗化精确匹配算法对患者进行匹配。主要结局是微血管(因皮瓣受损返回手术室、皮瓣丢失)和大血管(静脉血栓栓塞)并发症。
本研究共纳入506例患者(812块皮瓣)。11例患者(17块皮瓣)为FVL杂合子。匹配后,10例携带FVL的患者(16块皮瓣)与55例患者(94块皮瓣)匹配。FVL队列中因皮瓣受损返回手术室的比例为0%,而匹配对照中为5%(n = 5/94,3/94块皮瓣丢失,P = 1.00)(未匹配对照中为1.9%,n = 15/795,0.6%,n = 5/795为丢失率)。FVL患者中静脉血栓栓塞事件为零,而对照中为2%(n = 1/55)。
FVL杂合性并未增加接受腹壁下深动脉穿支皮瓣乳房重建患者发生微血管或大血管并发症的风险。本研究支持在给予适当的静脉血栓栓塞预防措施时,该组患者进行微血管重建的安全性。